Teclistamab
Checked 2026-09-09
Relapsed or refractory myeloma after 3 or more lines including a PI, IMiD and CD38 antibody
One cycle
weeklyComponents
| Drug | Dose | Route | Days | Note |
|---|---|---|---|---|
Teclistamab Bispecific T-cell engager (BCMA×CD3) | step-up 0.06 mg/kg and 0.3 mg/kg, then 1.5 mg/kg weekly | SC | D1 | step-up doses 2-4 days apart with inpatient monitoring |
Cycles
weekly until progression; every 2 weeks after 6 months in complete response
7-day cycle
Emetogenicity
Minimal (<10%)
G-CSF
Not routine
Notes
- CRS in 72% (mostly grade 1-2); infections in 76%: IVIG for hypogammaglobulinaemia, PJP and antiviral prophylaxis.
Used in
Trials
Products
Source
Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.
Other regimens for these cancers
Pegylated liposomal doxorubicin
Platinum-resistant or partially platinum-sensitive ovarian cancer; Kaposi sarcoma
every 28 days
VRd
Newly diagnosed myeloma (with daratumumab as D-VRd in transplant-eligible patients)
every 21 days × 8
D-VRd (PERSEUS)
Newly diagnosed transplant-eligible myeloma: 4 induction cycles, ASCT, 2 consolidation cycles, then D-R maintenance
every 28 days × 4
DRd (daratumumab + lenalidomide + dexamethasone)
Newly diagnosed transplant-ineligible myeloma (MAIA); relapsed myeloma (POLLUX)
every 28 days
High-dose melphalan and autologous stem-cell transplant
Transplant-eligible myeloma after induction
single day × 1
Lenalidomide maintenance
After autologous transplant
every 28 days